Efficacy and safety of etrasimod in Japanese patients with ulcerative colitis: results from a phase 2 dose-ranging study
Overall, etrasimod 2 mg QD for up to 12 weeks appeared efficacious and safe in these Japanese patients with moderately to severely active UC. All TEAEs were mild to moderate in severity. (ClinicalTrials.gov: NCT05061446).
Authors
- Hiroshi Nakase (ORCID: https://orcid.org/0000-0003-2848-6586)
- Toshifumi Hibi∥ (ORCID: https://orcid.org/0000-0002-6256-1204)
- Krisztina Lazin
- Michael J. Keating (ORCID: https://orcid.org/0000-0002-9121-6450)
- Ken Takeuchi (ORCID: https://orcid.org/0000-0002-9345-6503)
- Guibao Gu
- Kanako Fukuta
- Motoki Oe
- Katsuyoshi Matsuoka (ORCID: https://orcid.org/0000-0002-2950-7660)
- Shoko Arai (ORCID: https://orcid.org/0000-0003-4609-1609)
- Hirotoshi Yuasa (ORCID: https://orcid.org/0009-0007-2067-7392)
- Ryosuke Ono (ORCID: https://orcid.org/0000-0002-0125-4630)
- Aoibhinn McDonnell (ORCID: https://orcid.org/0000-0002-2229-0382)
- Tadakazu Hisamatsu
Institutions
- Toho University (JP)
- Sapporo Medical University (JP)
- Pfizer (United States) (US)
- Pfizer (United Kingdom) (GB)
- Kyorin University (JP)
- Pfizer (Switzerland) (CH)
- Toho University Medical Center Sakura Hospital (JP)
- Pfizer (Japan) (JP)
- Kitasato Institute Hospital (JP)
- Kitasato University (JP)
Publication Details
- Journal
- Intestinal Research
- Published
- 2025-04-25
- DOI
- https://doi.org/10.5217/ir.2024.00213
- Citations
- 1
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 1.82
Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- Gilead Sciences
- EA Pharma Co., Ltd.
- Kissei
- Miyarisan Pharmaceutical
- Celltrion
- Kyorin Pharmaceutical
- Mitsubishi Tanabe Pharma Corporation
- Pfizer Japan
- Eli Lilly Japan